Back to results
US 10,588,961 B2Granted
Poxviral vaccines
AssigneeGlaxosmithkline Biologicals SA
InventorsStefano Colloca, Riccardo Cortese, Antonella Folgori, Alfredo Nicosia
Life of this patent
Estimating the term…
Abstract
The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
Claims12
A method for stimulating an immune response comprising administering to a subject:
- (a) a Modified Vaccinia Ankara vector comprising a nucleic acid construct comprising:
- (i) a nucleic acid sequence encoding at least one antigenic protein or antigenic fragment thereof operatively linked to
- (ii) a nucleic acid encoding at least one invariant chain;
- and
- (b) an adenoviral vector comprising a nucleic acid sequence encoding at least a second antigenic protein or antigenic fragment thereof;
- wherein the second antigenic protein or antigenic fragment thereof is immunologically identical to the antigenic protein or antigenic fragment thereof encoded by the nucleic acid construct comprised by the Modified Vaccinia Ankara vector.
3 more elements
Dependencies are inferred from the claim text.